{"certainAgreement":{"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Enrollment of participants into Cohort 5 of this study was discontinued after the Food and Drug Administration (FDA) implemented a clinical hold after determining the risks of pembrolizumab + lenalidomide outweighed any potential benefit."},"pointOfContact":{"email":"ClinicalTrialsDisclosure@merck.com","organization":"Merck Sharp & Dohme Corp.","phone":"1-800-672-6372","title":"Senior Vice President, Global Clinical Development"}}